drugset / Trial / NCT02243735

Trial Comparing Ferric(III)Carboxymaltose Infusion With Oral Iron Suppletion as Treatment of Anaemia

NCT02243735

RandomizedParallel-groupOpen-labelTreatment

Summary

The aim of this multicenter trial is to determine the efficacy of preoperative intravenous iron suppletion in comparison with the standard preoperative oral substitution in anaemic patients with colorectal cancer in curing the anemia and the assess the effect of preoperative iron on morbidity, postoperative recovery and quality of life. Hypothesis: It is our hypothesis that a more profound approach of preoperative anaemia with intravenous iron will lead to a higher percentage of patients with normalization of Hb-level (\> 12 g/dl (7.5 mmol/l) for women and \> 13 g/dl (8 mmol/l) for men), which potentially reduces morbidity, length of stay, improves quality of live, decreases fatigue and could be more cost effective compared to current practice with oral substitution of iron.

Timeline

Start
2014-11
Primary completion
2019-11
Completion
2019-12

Drugs

EvaluationDrugModalityDoseRoute
Comparator Ferric carboxymaltose Other / unclassified 1 g Intravenous
Comparator Ferric carboxymaltose Other / unclassified 2 g Intravenous
Comparator Ferrous Sulfate Diagnostic / imaging agent 600 mg Oral